SCHEMBL1581636

SCHEMBL1581636

CCOC(=O)/C(=C/C1CCCC1)c1ccc(SCc2cccnc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ GFER P55789 6/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ C3AR1 Q16581 1/20 0.42
▸ TSHR P16473 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ CCNE2 O96020 1/20 0.37
▸ CCNE1 P24864 1/20 0.37
▸ CDK2 P24941 1/20 0.37
▸ PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1581637 1.00 SMN1; SMN2 (0.46) SMN1; SMN2LMNAGLAPOLBHPGD
SCHEMBL1582017 0.82 JAK1 (0.43) SMN1; SMN2LMNAHPGDALDH1A1C3AR1
SCHEMBL1582019 0.82 JAK1 (0.43) SMN1; SMN2LMNAHPGDALDH1A1C3AR1
SCHEMBL2647024 0.81 RAB9A (0.45) SMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL2647022 0.81 RAB9A (0.45) SMN1; SMN2POLBALDH1A1MAPK1
SCHEMBL1581786 0.78 ALDH1A1 (0.44) SMN1; SMN2LMNAPOLBALDH1A1TSHR
SCHEMBL1581789 0.78 ALDH1A1 (0.44) SMN1; SMN2LMNAPOLBALDH1A1TSHR
SCHEMBL1581782 0.77 MEN1 (0.35) SMN1; SMN2ALDH1A1HSD17B10KMT2A
SCHEMBL1581784 0.77 MEN1 (0.35) SMN1; SMN2ALDH1A1HSD17B10KMT2A
SCHEMBL1581896 0.77 ALDH1A1 (0.43) SMN1; SMN2LMNAPOLBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 — — EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 — — US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 — — US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 — — EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 SMN1; SMN2 4420/4885LMNA 4666/4885GLA 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback